Cargando…
Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children
BACKGROUND: The rise in community-acquired urinary tract infections (UTIs) with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli strains raises the question of how to treat these infections effectively in pediatric outpatients. Amikacin has shown promising in vitro activity against ES...
Autores principales: | Polat, Meltem, Kara, Soner Sertan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674974/ https://www.ncbi.nlm.nih.gov/pubmed/29138582 http://dx.doi.org/10.2147/IDR.S148703 |
Ejemplares similares
-
Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
por: Cho, Sung-Yeon, et al.
Publicado: (2016) -
Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections
por: Vachvanichsanong, P., et al.
Publicado: (2020) -
Complicated urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli
por: Ranjan, K. P., et al.
Publicado: (2014) -
Extended spectrum beta-lactamase urinary tract infections
por: Aboumarzouk, Omar M.
Publicado: (2014) -
Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates
por: Endo, Aiju, et al.
Publicado: (2022)